Recommended Doses for Leprosy Treatment
For multibacillary (MB) leprosy, the standard WHO multidrug therapy consists of rifampicin 600 mg once monthly (supervised), dapsone 100 mg daily (self-administered), and clofazimine 300 mg once monthly (supervised) plus 50 mg daily (self-administered) for 12 months. 1, 2
Multibacillary (MB) Leprosy - Standard Regimen
The WHO-recommended doses for MB leprosy are:
- Rifampicin: 600 mg once monthly under supervision
- Dapsone: 100 mg daily (self-administered)
- Clofazimine: 300 mg once monthly (supervised) + 50 mg daily (self-administered)
- Duration: 12 months 2
This triple-drug combination has proven highly successful in preventing relapse and reducing disability 2. The regimen can be shortened to 6 months (uniform MDT/U-MDT) with similar relapse rates of approximately 4-5% over 10 years, though this remains somewhat controversial 3.
Paucibacillary (PB) Leprosy
For PB leprosy, the regimen is simpler:
- Rifampicin: 600 mg once monthly (supervised)
- Dapsone: 100 mg daily (self-administered)
- Duration: 6 months 2
Single Lesion Leprosy
For single skin lesion leprosy, WHO recommends a single-dose regimen consisting of rifampicin 600 mg + ofloxacin 400 mg + minocycline 100 mg given as a single supervised dose in adults. 2
Alternative Regimen (ROM)
When patients cannot tolerate standard MDT due to adverse reactions or drug resistance, the ROM regimen is an alternative:
- Rifampicin: 600 mg once monthly
- Ofloxacin: 400 mg daily
- Minocycline: 100 mg daily
- Duration: Variable based on clinical response 4, 5
Studies show ROM causes fewer adverse drug reactions compared to standard MDT (33% vs 67% of patients experiencing reactions), with MDT conferring 2.51 times higher risk of developing adverse reactions 5.
Pediatric Dose Adjustments
While the evidence doesn't provide specific pediatric dosing tables, doses should be proportionally reduced for children based on body weight, with dapsone typically dosed at lower mg/kg equivalents 1.
Important Clinical Considerations
Dapsone dosing should start at 50 mg daily in adults and be titrated up to 100 mg daily as tolerated, particularly for dermatitis herpetiformis, though leprosy treatment typically begins at the full 100 mg dose 1. The FDA label specifies that dapsone levels are influenced by acetylation rates, and patients with high acetylation rates may require dosage adjustment 1.
Common Pitfalls
- Never use monotherapy: Dapsone or any single antimicrobial agent should never be used alone due to rapid development of resistance 6
- Supervised dosing is critical: Monthly rifampicin doses must be supervised to ensure compliance and prevent resistance 2, 7
- Monitor for adverse reactions: Dapsone causes the most adverse reactions (particularly hematologic), followed by rifampicin. Clofazimine causes characteristic skin pigmentation in 75-100% of patients 8, 5
- Drug resistance monitoring: Resistance rates have increased since 2009, with overall resistance at approximately 10%, higher in relapsed cases (14.26%) versus new cases (7.25%) 9
The once-monthly rifampicin schedule (1200 mg) has been studied and shows equivalent efficacy to daily dosing at one-tenth the cost, making it ideal for large-scale treatment programs 7. However, the standard WHO recommendation remains 600 mg monthly 2.